Cumulative cases and deaths over 50 years (2023–2072) of the strategies which were the most cost-effective as identified in step 1 in PNG
| Scenarios | No intervention | 1X at age 35 self-collected HPV S&T | 2X at age 30, 40 self-collected HPV S&T | 2X at age 35, 40 self-collected HPV S&T | 2X at age 35, 45 self-collected HPV S&T* | 3X at age 30, 35, 40 self-collected HPV S&T | 5-yearly (6X) 30–55 self-collected HPV S&T |
| Incidence | |||||||
| Cumulative cases over 2023–2072 | 108 204 | 88 509 | 74 623 | 75 323 | 77 183 | 65 852 | 52 158 |
| Cases averted (2023–2072) | – | 19 695 | 33 581 | 32 881 | 31 021 | 42 352 | 56 047 |
| Mortality | |||||||
| Cumulative deaths over 2023–2072 | 75 731 | 61 716 | 52 247 | 52 789 | 53 899 | 46 378 | 37 487 |
| Deaths averted (2023–2072) | – | 14 015 | 23 484 | 22 942 | 21 833 | 29 353 | 38 244 |
*WHO recommendation of cervical screening for cervical cancer elimination was added.
PNG, Papua New Guinea; S&T, screen and treat.